This is a working overview of Pentapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-30. Anything still debated is marked as such rather than presented as settled.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
== Epidemiology == In the United States, 1–8% of cancer patients are diagnosed with leptomeningeal disease, with approximately 110,000 cases per year. The exact incidence of leptomeningeal disease is difficult to determine, since gross examination at autopsy may overlook signs of leptomeningeal disease, and microscopic pathological inspection may be normal if the seeding is multifocal or if an unaffected area of the central nervous system (CNS) is examined.
== Signs and symptoms == The early clinical features of MCTD are nonspecific and may include fatigue, low-grade fever, myalgias, Raynaud phenomenon, swelling of the fingers or hands, arthralgia, esophageal reflux or dysmotility, acrosclerosis (also known as sclerodactyly), mild myositis, and various forms of pulmonary involvement. MCTD can affect nearly any organ system.
=== AI and data center regulation === In June 2026, Pritzker announced that the Illinois Department of Commerce and Economic Opportunity would suspend new state tax incentives for data center construction starting on July 1, 2026. The announcement came after the Illinois General Assembly failed to pass the POWER Act, which was legislation that would have required data centers to pay for and supply their own renewable energy, enter community benefits agreements, and report water usage. Pritzker took unilateral action after Speaker of Illinois House of Representatives Chris Welch said the pause did not have the House Democratic Caucus's support. Pritzker also said he opposed future "hyperscale" data centers in Illinois and rejected the idea of selling farmland to data center companies. On July 6, 2026, Pritzker signed into law Senate Bill 315, the Artificial Intelligence Safety Measures Act. The law regulates artificial intelligence (AI) with transparency and accountability rules for companies producing the largest AI models. The law was the first in the nation to require mandatory annual third-party audits and was opposed by TechNet, a coalition of technology sector executives, during debate in the Illinois General Assembly. The law was supported by artificial intelligence companies Anthropic and OpenAI and passed with bipartisan support, with only five state senators, all Republicans, voting against it.
=== Operation Enduring Freedom VI, 2005–2008 === The 1st Brigade of the 82nd deployed in April 2005 in support of OEF 6, and returned in April 2006. 1st Battalion, 325th Infantry Regiment deployed in support of OEF 6 from July through November 2005. In March 2006, 3rd Battalion (General Support), 82nd Aviation was selected to augment a special operations task force using CH-47 Chinooks and UH-60 Black Hawks. The task force consisted of 75th Ranger Regiment, Special Forces, and 160th Special Operations Aviation Regiment (Airborne). 2007 February 18, seven soldiers from the task force died in a helicopter crash. The deployment would end a month later (March 2007). In January 2007, then Maj. Gen. David M. Rodriguez deployed the division headquarters to Bagram Air Base, Afghanistan, accompanied by 4th BCT and the Aviation Brigade, as Commander, Combined Joint Task Force-82 (CJTF-82) and Regional Command – East for Operation Enduring Freedom VIII. The 3d BCT, 10th Mountain Division (Light Infantry) was extended for 120 days to increase the troop strength against the Taliban spring offensive. Extended to 15-month deployment, 4th BCT, which included 1–508th Infantry Regiment, 2–508th Infantry Regiment, and 4–73rd Cavalry Regiment, 2–321st Field Artillery, and 782nd Brigade Support Battalion, was commanded by then Col. Martin P. Schweitzer and remained in Khowst Province from January 2007 until April 2008. The 2–508th IR worked to establish and maintain firebases in and around the Ghazni province while actively patrolling their operational area.
=== Occupational and habitation rehabilitation === Thirty-three of the 50 planned work-sheds for gas victims started. All except one was closed down by 1992. In 1986, the MP government invested in the Special Industrial Area Bhopal. One hundred and fifty-two of the planned 200 work sheds were built and in 2000, 16 were partially functioning. It was estimated that 50,000 persons need alternative jobs, and that less than 100 gas victims had found regular employment under the government's scheme. The government also planned 2,486 flats in two- and four-storey buildings in what is called the "widow's colony" outside Bhopal. The water did not reach the upper floors and it was not possible to keep cattle which was their primary occupation. Infrastructure like buses, schools, etc. were missing for at least a decade.
Sources: en.wikipedia.org
== Assays for prolyl isomerase activity == Prolyl isomerase activity was first discovered using a chymotrypsin-based assay. The proteolytic enzyme chymotrypsin has a very high substrate specificity for the four-residue peptide Ala-Ala-Pro-Phe only when the proline peptide bond is in the trans state. Adding chymotrypsin to a solution containing a reporter peptide with this sequence results in the rapid cleavage of about 90% of the peptides, while those peptides with cis proline bonds - about 10% in aqueous solution - are cleaved at a rate limited by uncatalyzed proline isomerization. The addition of a potential prolyl isomerase will accelerate this latter reaction phase if it has true prolyl isomerase activity.
Nando's opened its first restaurant location within the United States in Washington, D.C. in 2008. After opening more outlets within the Washington metropolitan area, it expanded into the Chicago metropolitan area, opening its first outlet on 20 May 2015 within the metro area. As of February 2026, there are 46 restaurant outlets in five states and the District of Columbia: 12 in Illinois, six in Washington, D.C., 10 in Maryland, 11 in Virginia, two in Georgia, and five in Texas.
Polish Women's Alliance of America Sons of Poland Union of Polish Women of America - Founded on October 17, 1920, in Philadelphia by women who had previously been active in the Red Cross, White Cross, Emergency Aid and Polish War Mothers. Local units are called "Branches", regional structures are called "Districts", and there are also youth "Juvenile Circles". National convention meets quadrennially, at which point a "convention Queen" is crowned to reign for four years. "Supreme Executive Body" runs the organization between conventions. In 1979 membership was open to people of Polish origin or their spouses. 1979 membership. The motto is "Unity, Stability, and Prosperity". Strong connections with the Catholic Church. Grants "partial scholarships" and educational loans to Americans of Polish descent.
== History == Although genetics has its roots back in the 19th century with the work of the Bohemian monk Gregor Mendel and other pioneering scientists, human genetics emerged later. It started to develop, albeit slowly, during the first half of the 20th century. Mendelian (single-gene) inheritance was studied in a number of important disorders such as albinism, brachydactyly (short fingers and toes), and hemophilia. Mathematical approaches were also devised and applied to human genetics. Population genetics was created. Medical genetics was a late developer, emerging largely after the close of World War II (1945) when the eugenics movement had fallen into disrepute. The Nazi misuse of eugenics sounded its death knell. Shorn of eugenics, a scientific approach could be used and was applied to human and medical genetics. Medical genetics saw an increasingly rapid rise in the second half of the 20th century and continues in the 21st century.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.